What side effects should be monitored in a patient receiving haloperidol?

Side Effects to Monitor in Patients on Haloperidol

Monitor closely for extrapyramidal symptoms (EPS), cardiovascular effects including QT prolongation and sudden death, neuroleptic malignant syndrome, tardive dyskinesia, and metabolic/hematologic abnormalities, as these represent the most serious and common adverse effects of haloperidol therapy.

Extrapyramidal Symptoms (EPS) – Most Common Side Effect

Acute Dystonia

• Sudden spastic muscle contractions affecting the neck (torticollis), eyes (oculogyric crisis), jaw, tongue, or trunk typically occur within the first few days of treatment 1, 2.
• Young males are at highest risk for acute dystonic reactions 1, 2.
• Treat immediately with benztropine 1–2 mg IM/IV or diphenhydramine 25–50 mg IM/IV for rapid symptom relief 1, 2.

Drug-Induced Parkinsonism

• Monitor for bradykinesia (slowed movements), tremor, rigidity, and shuffling gait that develop gradually over days to weeks 1, 2.
• Elderly patients are at higher risk than younger individuals 1.
• Management includes dose reduction first, then switching to a lower-risk atypical antipsychotic (quetiapine, olanzapine, clozapine) if symptoms persist 2.

Akathisia

• Watch for subjective inner restlessness with inability to sit still, pacing, fidgeting, and physical agitation that is often misinterpreted as worsening psychosis or anxiety 1, 2.
• Akathisia is a major cause of medication non-compliance 2.
• Propranolol or benzodiazepines (lorazepam) are more effective than anticholinergics for akathisia management 1, 3.

Tardive Dyskinesia

• Screen for involuntary choreiform movements of the face, mouth, tongue (lip smacking, tongue protrusion, chewing), and extremities that emerge after months to years of antipsychotic exposure 1, 4.
• Risk is approximately 5% per year in young patients and highest in elderly women 1.
• Potentially irreversible even after drug discontinuation; prevention through lowest effective dose and shortest duration is critical 4.
• Use standardized rating scales every 3–6 months to detect early signs 2.

Cardiovascular Effects – Potentially Fatal

QT Prolongation and Torsades de Pointes

• Obtain baseline ECG before initiating haloperidol and monitor QTc interval, especially when using doses >5 mg or in high-risk patients 1, 4, 5.
• QTc prolongation >500 ms significantly increases risk of torsades de pointes (polymorphic ventricular tachycardia) 1, 6.
• Risk factors include electrolyte abnormalities (hypokalemia, hypomagnesemia), concurrent QT-prolonging drugs, underlying cardiac disease, hypothyroidism, and familial long QT syndrome 4.
• Higher doses (>5 mg) are associated with greater QT prolongation risk, though cases have occurred even at therapeutic doses 4, 5.

Hypotension and Cardiovascular Collapse

• Monitor for transient hypotension, particularly in patients with severe cardiovascular disorders 4.
• Avoid epinephrine for hypotension treatment, as haloperidol blocks its vasopressor activity and causes paradoxical further blood pressure lowering; use metaraminol, phenylephrine, or norepinephrine instead 4.

Sudden Death

• Elderly patients with dementia have 1.6–1.7 times higher mortality risk compared to placebo when treated with antipsychotics including haloperidol 4, 7.
• Cases of sudden death have been reported, particularly with higher doses 4.

Neuroleptic Malignant Syndrome (NMS) – Medical Emergency

• Watch for the tetrad of hyperthermia (fever up to 41°C or higher), altered mental status, severe muscle rigidity, and autonomic instability (tachycardia, blood pressure fluctuations, diaphoresis) 1, 4.
• NMS is potentially fatal with historical mortality rates of 76% (now reduced to 10–15% with early recognition) 1.
• Occurs in 0.02–3% of patients exposed to antipsychotics 1.
• Risk factors include coadministration of multiple psychotropic agents, dehydration, physical exhaustion, and organic brain disease 1.
• Immediate discontinuation of haloperidol and supportive care (cooling, hydration, dantrolene or bromocriptine) are essential 1.

Hematologic Abnormalities

Leukopenia, Neutropenia, and Agranulocytosis

• Monitor complete blood count (CBC) frequently during the first few months of therapy, especially in patients with preexisting low WBC or history of drug-induced leukopenia 4.
• Discontinue haloperidol immediately at the first sign of WBC decline without other causative factors 4.
• Patients with severe neutropenia (absolute neutrophil count <1,000/mm³) should discontinue haloperidol and have WBC monitored until recovery 4.
• Fatal cases of agranulocytosis have been reported 4.

Seizures

• Haloperidol lowers the seizure threshold in a dose-dependent manner 1, 4.
• Use cautiously in patients receiving anticonvulsants, with seizure history, or with EEG abnormalities 4.
• Maintain adequate anticonvulsant therapy concomitantly if indicated 4.

Metabolic and Endocrine Effects

Hyperprolactinemia

• Monitor for galactorrhea, amenorrhea, gynecomastia, and sexual dysfunction 4.
• Prolactin elevation persists during chronic administration and may be associated with increased breast cancer risk in susceptible individuals 4.

Weight Gain and Metabolic Syndrome

• Although less prominent than with atypical antipsychotics, monitor weight, glucose, and lipids at baseline, 3 months, and annually 1.

Anticholinergic Effects

• Watch for dry mouth, constipation, urinary retention, blurred vision, confusion, and paradoxical agitation 1.
• Anticholinergic burden worsens cognitive function in elderly patients and those with dementia 1, 8.

Respiratory Depression

• Risk increases when haloperidol is combined with benzodiazepines or opioids 1.
• Haloperidol alone has lower respiratory depression risk than benzodiazepines 1.

Monitoring Protocol Summary

Before Initiating Haloperidol

• Baseline ECG to assess QTc interval 1, 4, 5.
• CBC with differential to establish baseline WBC 4.
• Electrolytes (potassium, magnesium) to identify risk factors for QT prolongation 4.
• Liver function tests 1.
• Baseline movement examination to document any preexisting abnormalities 2.

During Treatment

• Daily in-person assessment for ongoing need, EPS, falls, sedation, and vital signs 1.
• ECG monitoring when using doses >5 mg or in high-risk patients (cumulative doses ≥100 mg, QTc >500 ms) 5.
• Monitor for EPS signs at every visit: tremor, rigidity, bradykinesia, akathisia, dystonia 1, 2.
• Tardive dyskinesia screening every 3–6 months using standardized scales 1, 2.
• CBC monitoring if patient develops fever, infection signs, or has risk factors for leukopenia 4.
• Reassess need for continued treatment periodically; use lowest effective dose for shortest duration 4.

Common Pitfalls to Avoid

• Do not exceed 5 mg/day in elderly patients, as higher doses provide no additional benefit and markedly increase adverse effects 1, 9.
• Do not combine high-dose haloperidol with benzodiazepines due to increased risk of respiratory depression and oversedation 1.
• Do not ignore early EPS signs; they predict higher risk of tardive dyskinesia with continued exposure 1, 2.
• Do not continue haloperidol indefinitely without reassessment; approximately 47% of patients are discharged on antipsychotics without clear indication 1.
• Do not use prophylactic anticholinergics routinely; reserve for treatment of significant symptoms after they develop 2.